Histology
Invasive Carcinoma
CI-CAN-00001040Explore in graph →
603 active trials9 approved drugs37 evidence items
- NCIt
- C9480
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001040Explore in graph →
Clinical trials
1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07187063 | Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer | recruiting | N/A | 56 | Lahey ClinicOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05795101 | TRUDI: TDXD+Durva in HER2+/Low IBC(TRUDI) | recruiting | Phase 2 | 63 | Filipa Lynce, MDOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07179783 |
| Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) |
| recruiting |
| Phase 2 |
| 28 |
| Tianjin Medical University Second HospitalOTHER |
| 1 |
| Sep 18, 2025 |
| clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04794322 | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | recruiting | — | 250 | Massachusetts General HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer(PELICAN) | active not recruiting | Phase 2 | 52 | Institut Paoli-CalmettesOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT01655836 | High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 1 | 42 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05998135 | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05600400 | Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer(iSMART) | recruiting | N/A | 144 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07117877 | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer | not yet recruiting | Phase 2 | 33 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT05113368 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | recruiting | Phase 2 | 31 | Sarah K. Lynam MDOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06181266 | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer(PARADIGM-1) | active not recruiting | Phase 1 | 22 | Prokarium LtdINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05027477 | A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer(CAPTAIN) | active not recruiting | N/A | 201 | Profound Medical Inc.OTHER | 3 | Aug 17, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06976892 | Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer(IDOL) | recruiting | Phase 1 | 33 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07100288 | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer(INFPELV) | recruiting | — | 200 | Complejo Hospitalario Universitario Insular Materno InfantilOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07075250 | Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study(RIFOC003) | not yet recruiting | Phase 4 | 30 | Peking University People's HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07067255 | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer(BAH2573-104) | recruiting | Phase 1 / Phase 2 | 80 | Essen BiotechOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07068178 | Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study(ICI-HIPET) | not yet recruiting | Phase 2 | 30 | Jing LiOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT06292286 | Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer(SCENIC) | recruiting | N/A | 18 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06991868 | A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) | recruiting | — | 300 | Peking University First HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06982690 | Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial | not yet recruiting | N/A | 370 | National Taiwan University HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06766266 | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment | recruiting | Phase 1 | 18 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06889623 | Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer(HIGCrecur) | recruiting | N/A | 72 | Changhai HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06735287 | A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer | recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06475261 | Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06283511 | Evaluation of the RESTART Survival Programme | not yet recruiting | — | 200 | Jules Bordet InstituteOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT06850545 | Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer(KuPSMALu) | recruiting | — | 150 | Kuopio University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 22, 2025source: clinicaltrials